Pharmacyclics, Inc., a pharmaceutical company, is developing drugs to treat cancer and other diseases. Its pharmaceutical agents are synthetic small molecules designed to target key biochemical pathways in diseased cells. The company’s product candidate, Xcytrin (motexafin gadolinium) Injection, an anti-cancer agent with a novel mechanism of action, has completed Phase III trials in oncology and is in Phase II trials for patients with non-small cell lung cancer. Its products also include PCI-24781, a histone deacetylase inhibitor in Phase I trial in patients with advanced relapsed solid tumors; PCI-24783, a preclinical stage small molecule inhibitor of Factor VIIa for cancer therapy; and PCI-32765, a preclinical stage small molecule tyrosine kinase inhibitor to treat B cell malignancies and autoimmune disease. Pharmacyclics has a license agreement with the University of Texas to develop and commercialize porphyrins, expanded porphyrins, and other porphyrin-like substances covered by its patents. The company was founded in 1991 and is headquartered in Sunnyvale, California.
Analysts'
Recommendation: | Buy |
| 30 Days Ago: | Buy |
$1.8 (06/27/08)
